Stock Financial Ratios


RTTR / Ritter Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.34
Volume244,300.00
Market Cap ($M)5.02
Enterprise Value ($M)-2.27
Book Value ($M)4.10
Book Value / Share0.46
Price / Book4.17
NCAV ($M)4.10
NCAV / Share0.46
Price / NCAV4.21
Income Statement (mra) ($M)
Revenue0.00
EBITDA-18.45
Net Income-18.38
Balance Sheet (mrq) ($M)
Cash & Equivalents3.56
Cash / Share0.40
Assets4.16
Liabilities2.96
Quick Ratio2.30
Current Ratio2.30
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-4.48
Return on Assets (ROA)-2.54
Return on Equity (ROE)-4.48
Identifiers and Descriptors
CUSIP767836109
Central Index Key (CIK)1460702
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)49.51
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Additional Paid In Capital Per Share5.82
Assets Current Per Share0.42
Cash And Equivalents Per Share0.40
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Retained Earnings Per Share-5.68
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Cash Per Share0.40
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Liabilities And Stock Equity Per Share0.46
Inventory Per Share0.00
Liabilities Current Per Share0.33
Assets Other Non Current Per Share0.00
Liabilities Per Share0.33
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Assets Per Share0.46
Property Plant And Equipment Net Per Share0.00
Equity Per Share0.13

Stock Research Report

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. The company completed a Phase 2a clinical trial of its leading product candidate, RP-G28, an orally administered, high purity oligosaccharide in November 2011.

The company completed a Phase 2b/3 multi-center, randomized, double-blind, placebo-controlled, parallel group trial of RP-G28 in October 2016. The purpose of the trial was to evaluate the safety, efficacy and tolerability of two dosing regimens of RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March 2016 and completed in August 2016, achieving its projected enrollment time pe...

Click for full article

Related News Stories

Tile Shop, Ritter Pharmaceuticals Plunge into Tuesday’s 52-Week Low Club

2017-10-03 247wallst
October 3, 2017: Here are four stocks trading with heavy volume among 29 equities making new 52-week lows in Tuesday’s session. On the NYSE, advancers led decliners by more than 8 to 7 and on the Nasdaq advancers led decliners by about 4 to 3. (20-3)

BRIEF-‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals

2017-10-03 reuters
* ‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing Source text : bit.ly/2yWkm3T Further company coverage: (15-2)

BRIEF-RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE

2017-10-03 reuters
* RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE (15-1)

Avon, Rite Aid Slide into Friday’s 52-Week Low Club

2017-09-30 247wallst
September 29, 2017: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Friday’s session. On the NYSE, advancers led decliners by about 3 to 2 and on the Nasdaq advancers led decliners by about the same ratio. (172-1)

BRIEF-Ritter Pharmaceuticals Inc prices $23,000,000 public offering

2017-09-29 reuters
* Ritter Pharmaceuticals Inc - offering is expected to close on October 3, 2017 Source text for Eikon: Further company coverage: (15-4)

CUSIP: 767836109